Cyclo Therapeutics Licenses MIT Patent to Target Alzheimer's in ApoE4 Carriers
Rafael Holdings secures exclusive MIT patent rights for cyclodextrins in ApoE4-positive Alzheimer's patients, a group representing up to 70% of cases.
Summary
Rafael Holdings, through its subsidiary Cyclo Therapeutics, has secured an exclusive license from MIT covering the use of cyclodextrins in Alzheimer's patients who carry the ApoE4 gene variant. This variant is found in 50 to 70 percent of Alzheimer's cases and raises the risk of earlier disease onset. The licensed compound, Trappsol Cyclo, works by improving cholesterol transport between brain cells — a process disrupted in ApoE4 carriers and linked to the buildup of amyloid and tau proteins associated with Alzheimer's. Preclinical mouse studies showed reduced tau pathology and improved learning and memory. Phase 3 trial results from the Transport NPC study are expected in mid-2026, which could be a pivotal moment for this therapeutic approach.
Detailed Summary
Rafael Holdings has announced that its subsidiary, Cyclo Therapeutics, has entered an exclusive licensing agreement with MIT for a patent covering the use of cyclodextrins in Alzheimer's patients who carry the ApoE4 genetic variant. This move is designed to strengthen the company's intellectual property position around its lead compound, Trappsol Cyclo, specifically in this high-risk patient population.
The ApoE4 variant is one of the most significant known genetic risk factors for Alzheimer's disease, estimated to be present in 50 to 70 percent of all Alzheimer's patients. Carriers tend to develop the disease earlier and often have more aggressive progression. Targeting this subgroup represents a precision medicine approach that could meaningfully improve outcomes if the therapy proves effective.
Trappsol Cyclo's proposed mechanism centers on restoring cholesterol transport between central nervous system cells. In ApoE4 carriers, this transport is impaired, and the company argues this disruption contributes to the accumulation of amyloid plaques and tau tangles — the hallmark pathologies of Alzheimer's. Preclinical data in mice showed that the compound improved cholesterol delivery in the brain, reduced tau pathology, and enhanced learning and memory performance.
The most critical near-term milestone is the Phase 3 readout from the Transport NPC study, expected in the third quarter of 2026. Rafael Holdings describes its NPC1 Phase 3 trial as the largest ever conducted in that patient group, which adds weight to the upcoming data. Positive results could accelerate regulatory pathways and validate cyclodextrins as a viable Alzheimer's intervention.
Important caveats apply. The current evidence base is largely preclinical, and the press release is a corporate announcement rather than peer-reviewed research. Phase 3 results will be the true test of whether this mechanism translates to human benefit. Investors and clinicians should await those data before drawing firm conclusions.
Key Findings
- ApoE4 variant present in 50–70% of Alzheimer's patients; cyclodextrins may specifically address this subgroup's cholesterol transport defect.
- Trappsol Cyclo targets impaired CNS cholesterol transport in ApoE4 carriers, a pathway linked to amyloid and tau pathology.
- Preclinical mouse data showed reduced tau pathology and improved learning and memory with cyclodextrin treatment.
- Phase 3 Transport NPC trial results expected Q3 2026, described as the largest NPC1 trial ever conducted.
- MIT exclusive patent license strengthens IP protection for Trappsol Cyclo in the ApoE4-positive Alzheimer's population.
Methodology
This is a corporate press release summarized as a news report by Longevity.Technology; it is not a peer-reviewed study. Evidence cited includes preclinical mouse data and an ongoing Phase 3 trial, with no published clinical efficacy data yet available. Forward-looking statements and commercial interests should be weighed when interpreting claims.
Study Limitations
All efficacy data cited are preclinical (mouse models), which frequently do not translate to human outcomes. The source is a corporate press release with inherent promotional bias and no independent peer review. Phase 3 results expected in 2026 will be essential to verify whether the mechanism produces meaningful clinical benefit in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.